Abstract In lung cancer, early detection and diagnosis is of paramount importance. In 2011 the National Lung Screening Trial (NLST) demonstrated the effectiveness of computed tomography (CT) screening for lung cancer in reducing mortality, and results from other ongoing trials are expected to be published in the near future. A topic that has not been widely researched to date, however, is the cause for screening failure and missed lung cancers. In lung cancer screening with thoracic computed tomography (CT), there are some parallels but also dissimilarities concerning this issue. The ability of readers to detect lung nodules on CT has certainly been the subject of extensive investigation. In mainly research conditions, it has been shown that even experienced thoracic radiologists may demonstrate only moderate performance in nodule detection [3, 4] . However, in contrast to the plain chest radiograph, much emphasis has also been placed on the issue of minimizing "overcalls" (i.e., false-positive nodules) in CT screening. The topic of false negatives in lung cancer screening has gained less attention, which is perhaps a reflection of its very high negative predictive value (>99 %) [5, 6] .
Missed lung cancers on chest radiographs are a well recognised source of litigation in radiology [1] . While it may be intuitive to think that most missed lung cancers on chest radiographs are due to failures of detection, previous evidence suggests that often missed lung cancers are detected but misinterpreted as benign opacities or normal structures at the time of reporting [2] .
In lung cancer screening with thoracic computed tomography (CT), there are some parallels but also dissimilarities concerning this issue. The ability of readers to detect lung nodules on CT has certainly been the subject of extensive investigation. In mainly research conditions, it has been shown that even experienced thoracic radiologists may demonstrate only moderate performance in nodule detection [3, 4] . However, in contrast to the plain chest radiograph, much emphasis has also been placed on the issue of minimizing "overcalls" (i.e., false-positive nodules) in CT screening. The topic of false negatives in lung cancer screening has gained less attention, which is perhaps a reflection of its very high negative predictive value (>99 %) [5, 6] .
In this issue of European Radiology, the publication by Scholten and colleagues [7] of the NELSON trial is one of the few recent CT lung cancer screening studies to report on the causes of missed lung cancers. In this study, 22 missed lung cancers are described, which were visible in retrospect on the previous screening thoracic CT. What is revealing is not that the majority of misses were due to errors of detection, but rather that in most, there was an "explanation" for the miss.
For example, in 5/22 cases, the overlooked opacity manifested as a small endobronchial lesion, in 3/22 cases as mediastinal or hilar lymph nodes, and in 5/22 cases as thickening of a bulla wall. Only in 2/22 cases (both intra-parenchymal nodules) could no explanation be provided other than observational error.
The concept of bulla wall thickening as a marker of lung cancer is worthy of discussion. The association between lung cancer and bullae has long been recognized on plain radiographs [8] , and this phenomenon has also gained attention recently in CT studies [9] . However, malignant and benign opacities in areas of emphysema demonstrate considerable overlap in appearances [10] , and so, how such opacities should be managed lacks consensus.
A number of questions arise: what degree of bulla wall thickness should prompt early follow-up CT or further investigation? What extent of the bulla wall should be involved before malignancy is considered? Is nodular thickening of the bulla wall of more concern compared to diffuse thickening?
Further questions, currently unanswered, are also raised about the optimal management protocols in screening for other types of "atypical" opacities; for example, apical scar-like nodules (which incidentally was also identified as a cause of a missed lung cancer in this study), or para-osteophyte opacities that likely represent focal fibrosis, or endobronchial opacities that are probably mucus. Should these opacities be treated in the same manner as typical indeterminate lung nodules, and mandate follow-up CT if above a predefined size?
Analysis of large numbers of nodules from completed or ongoing lung cancer screening trials has already provided invaluable data to assist in the management of "typical" lung nodules, by identifying characteristics predictive of malignancy [5, 11] . The National Lung Screening Trial (NLST), for example, has reported the positive predictive values for malignancy according to lung nodule size, based on an analysis of more than 7000 individuals with nodules. The same trial also reports the positive predictive value of mediastinal or hilar lymphadenopathy for malignancy (18 %) [5] .
To provide similar evidence to guide the management of "atypical" opacities such as bulla wall thickening would require the analysis of large numbers of CTs demonstrating these lesions in patients without lung cancer. This is something which is currently lacking, and may not be forthcoming. Regardless, radiologists should be alert to the possibility that nodular thickening of a bulla wall may represent malignancy. The demonstration of progressive thickening on serial CTs should be sufficient to trigger pulmonologist or multidisciplinary team (MDT) referral in most cases.
It is noteworthy that in the current study by Scholten and colleagues, false-negative CT screens were due to a variety of reasons, not just observational oversight. Eight cases were due to lack of patient adherence, three due to failure of invasive workup, two due to failure of the protocol, and in 11 cases because of the rapidity of tumour development following a negative screen. In combination, these miscellaneous causes were more common than radiological error.
Just as there is no universally accepted definition for what constitutes a false positive in lung cancer screening, no such definition exists for false negatives. It should be stressed that the current study only reports on missed cancers identified after screening had finished or cancers which presented between screening rounds (interval cancers). As the authors acknowledge, equally informative data could be obtained by scrutinizing false-negative cases where cancer was diagnosed at subsequent screening rounds, but which was identifiable on a previous CT.
Veronesi et al. [12] recently described the causes of false negatives in the COSMOS lung cancer screening study. They included within their definition of false negatives, lung cancers that were diagnosed at the time of screening which were evident as a nodule on a prior CT, but only if the lung cancer was stage II-IV (i.e., if there was a significant delay in diagnosis as demonstrated by stage progression). Interestingly, in this study [12] , as in the study by Scholten et al. [7] and other previous reports [13] , centrally located or endobronchial lesions are disproportionately represented in missed lung cancers.
Computer aided detection systems (CAD) have long been known to be more sensitive in nodule detection than human readers. Currently, considerable efforts are being devoted to tackle its limitations, such as improving the detection of ground glass nodules [14] . Knowledge gained from articles such as the one by Scholten et al. [7] of the characteristics of missed lung cancers may provide useful guidance for future CAD development. In the interim, it also serves to remind radiologists of their known blind spots. 
